-
公开(公告)号：US20070021330A1
公开(公告)日：2007-01-25
申请号：US10561718
申请日：2004-05-19
申请人： Frank Wu , Suanne Nakajima , Yat Or , Zhi-Hui Lu , Ying Sun , Zhenwei Miao , Zhe Wang
发明人： Frank Wu , Suanne Nakajima , Yat Or , Zhi-Hui Lu , Ying Sun , Zhenwei Miao , Zhe Wang
IPC分类号： A61K38/12 , C07K5/12 , A61K31/4709
CPC分类号： C07K5/06139 , A61K38/00 , C07K5/06165
摘要： The present invention relates to compounds of Formula (I), or a pharmaceutically acceptable salt, ester, or prodrug, thereof, which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
摘要翻译： 本发明涉及抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶活性的式（I）化合物或其药学上可接受的盐，酯或前药。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。
-
2.发明申请公开(公告)号：US20050065073A1
公开(公告)日：2005-03-24
申请号：US10613206
申请日：2003-07-03
申请人： Frank Wu , Suanne Nakajima , Zhi-Hui Lu , Ying Sun , Zhenwei Miao , Yat Or , Zhe Wang
发明人： Frank Wu , Suanne Nakajima , Zhi-Hui Lu , Ying Sun , Zhenwei Miao , Yat Or , Zhe Wang
CPC分类号： C07K5/06139 , A61K38/00 , C07K5/06165
摘要： The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
摘要翻译： 本发明涉及抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶活性的式I化合物或其药学上可接受的盐，酯或前药。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。
-
公开(公告)号：US20050153877A1
公开(公告)日：2005-07-14
申请号：US10774047
申请日：2004-02-06
申请人： Zhenwei Miao , Ying Sun , Suanne Nakajima , Datong Tang , Frank Wu , Guoyou Xu , Yat Or , Zhe Wang
发明人： Zhenwei Miao , Ying Sun , Suanne Nakajima , Datong Tang , Frank Wu , Guoyou Xu , Yat Or , Zhe Wang
CPC分类号： C07D487/04 , A61K38/12 , C07K5/0806 , E05F15/73 , E05F2015/763
摘要： The present invention relates to compounds of Formula I, II or Ill, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: wherein W is a substituted or unsubstituted heterocyclic ring system. The compounds inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
摘要翻译： 本发明涉及式I，II或III的化合物或其药学上可接受的盐，酯或前药：其中W是取代或未取代的杂环体系。 该化合物抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。
-
4.发明授权公开(公告)号：US07125845B2
公开(公告)日：2006-10-24
申请号：US10613206
申请日：2003-07-03
申请人： Frank X. H. Wu , Suanne Nakajima , Zhi-Hui Lu , Ying Sun , Zhenwei Miao , Yat Sun Or , Zhe Wang
发明人： Frank X. H. Wu , Suanne Nakajima , Zhi-Hui Lu , Ying Sun , Zhenwei Miao , Yat Sun Or , Zhe Wang
IPC分类号： A61K38/00
CPC分类号： C07K5/06139 , A61K38/00 , C07K5/06165
摘要： The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
摘要翻译： 本发明涉及抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶活性的式I化合物或其药学上可接受的盐，酯或前药。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。
-
公开(公告)号：US20070161575A1
公开(公告)日：2007-07-12
申请号：US11602586
申请日：2006-11-20
申请人： Zhenwei Miao , Ying Sun , Suanne Nakajima , Datong Tang , Zhe Wang , Yat Or
发明人： Zhenwei Miao , Ying Sun , Suanne Nakajima , Datong Tang , Zhe Wang , Yat Or
CPC分类号： C07K5/0808 , A61K38/00
摘要： The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
-
公开(公告)号：US20050261200A1
公开(公告)日：2005-11-24
申请号：US10849107
申请日：2004-05-19
申请人： Zhenwei Miao , Ying Sun , Suanne Nakajima , Datong Tang , Zhe Wang , Yat Or
发明人： Zhenwei Miao , Ying Sun , Suanne Nakajima , Datong Tang , Zhe Wang , Yat Or
CPC分类号： C07K5/0808 , A61K38/00
摘要： The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
摘要翻译： 本发明涉及抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶活性的式I化合物或其药学上可接受的盐，酯或前药。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。
-
公开(公告)号：US20070060510A1
公开(公告)日：2007-03-15
申请号：US11489011
申请日：2006-07-18
申请人： Suanne Nakajima , Zhenwei Miao , Ying Sun , Datong Tang , Guoyou Xu , Brian Porter , Yat Or , Zhe Wang
发明人： Suanne Nakajima , Zhenwei Miao , Ying Sun , Datong Tang , Guoyou Xu , Brian Porter , Yat Or , Zhe Wang
IPC分类号： A61K38/12 , A61K31/497 , C07K5/12 , C07D487/14
CPC分类号： C07K5/0802 , A61K38/212 , A61K38/215 , C07D487/04 , C07K5/0804 , A61K2300/00
摘要： The present invention relates to compounds of Formula I or II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
摘要翻译： 本发明涉及抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶活性的式I或II化合物或其药学上可接受的盐，酯或前药。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。
-
公开(公告)号：US20090304629A1
公开(公告)日：2009-12-10
申请号：US12351144
申请日：2009-01-09
申请人： Zhenwei Miao , Ying Sun , Suanne Nakajima , Datong Tang , Frank Wu , Guoyou Xu , Yat S. Or , Zhe Wang
发明人： Zhenwei Miao , Ying Sun , Suanne Nakajima , Datong Tang , Frank Wu , Guoyou Xu , Yat S. Or , Zhe Wang
CPC分类号： C07D487/04 , A61K38/12 , C07K5/0806 , E05F15/73 , E05F2015/763
摘要： The present invention relates to compounds of Formula I, II or III, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: wherein W is a substituted or unsubstituted heterocyclic ring system. The compounds inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
摘要翻译： 本发明涉及式I，II或III的化合物或其药学上可接受的盐，酯或前药：其中W是取代或未取代的杂环体系。 该化合物抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。
-
公开(公告)号：US07601709B2
公开(公告)日：2009-10-13
申请号：US10774047
申请日：2004-02-06
申请人： Zhenwei Miao , Ying Sun , Suanne Nakajima , Datong Tang , Frank Wu , Guoyou Xu , Yat S. Or , Zhe Wang
发明人： Zhenwei Miao , Ying Sun , Suanne Nakajima , Datong Tang , Frank Wu , Guoyou Xu , Yat S. Or , Zhe Wang
IPC分类号： C07D245/00 , C07D487/00 , A61K31/33 , A01N43/00
CPC分类号： C07D487/04 , A61K38/12 , C07K5/0806 , E05F15/73 , E05F2015/763
摘要： The present invention relates to compounds of Formula I, II or Ill, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: wherein W is a substituted or unsubstituted heterocyclic ring system. The compounds inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
摘要翻译： 本发明涉及式I，II或III的化合物或其药学上可接受的盐，酯或前药：其中W是取代或未取代的杂环体系。 该化合物抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。
-
公开(公告)号：US08124584B2
公开(公告)日：2012-02-28
申请号：US12351144
申请日：2009-01-09
申请人： Zhenwei Miao , Ying Sun , Suanne Nakajima , Datong Tang , Frank Wu , Guoyou Xu , Yat Sun Or , Zhe Wang
发明人： Zhenwei Miao , Ying Sun , Suanne Nakajima , Datong Tang , Frank Wu , Guoyou Xu , Yat Sun Or , Zhe Wang
IPC分类号： A61K38/00
CPC分类号： C07D487/04 , A61K38/12 , C07K5/0806 , E05F15/73 , E05F2015/763
摘要： The present invention relates to compounds of Formula I, II or III, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: wherein W is a substituted or unsubstituted heterocyclic ring system. The compounds inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
摘要翻译： 本发明涉及式I，II或III的化合物或其药学上可接受的盐，酯或前药：其中W是取代或未取代的杂环体系。 该化合物抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。
-
-
-
-
-
-
-
-
-
搜索结果
24 条记录 (耗时 0.042 秒)
